Abstract 579P
Background
Dacomitinib demonstrated superior survival benefit compared to gefitinib as a first-line treatment in EGFR-mutant non-small cell lung cancer (NSCLC) patients through the phase 3 trial, ARCHER 1050 study. However, there is a lack of real-world data regarding the efficacy of dacomitinib and further sequential treatments after failure of dacomitinib.
Methods
This study included patients with advanced EGFR-mutant NSCLC who received first-line dacomitinib between January 2021 and December 2022 at Samsung Medical Center and St. Vincent Hospital. This study evaluated objective response rate (ORR), progression-free survival (PFS), safety of dacomitinib, and subsequential treatment after failing dacomitinib.
Results
In total, this study included 153 patients, with a median age of 63.7 years. Exon 19 deletion was observed in 50.3%, while the L858R mutation in exon 21 was observed in 46.4% of patients. The ORR was 84.3%. Median follow-up duration was 16.9 months, and the median PFS was 16.7 months (95% CI, 14.4, 25.2). According to type of EGFR mutation, the median PFS was 18.1 months (95% CI, 14.5, not reached) in patients with exon 19 deletion, and 15.9 months (95% CI, 12.5, not reached) in patients with L858R mutation in exon 21. Grade 3 or higher adverse events were observed in 7.2% of patients, with skin rash occurring in 4.6% and diarrhea in 2.0%. Dose reduction of dacomitinib occurred in 85.6% of patients, with a final dose of 30mg in 49.0% and 15mg in 36.6%. Among the 60 patients who experienced disease progression, 32 patients underwent tissue re-biopsy, while among the remaining, 24 patients underwent liquid biopsy. Overall, T790M mutation was detected in 40% of patients who progressed to dacomitinib.
Conclusions
This study highlights the efficacy of dacomitinib as a promising first-line treatment for patients with EGFR-mutant NSCLC in a real-world setting. The detection rate of T790M mutation after dacomitinib treatment failure was similar to that of other 2nd generation EGFR-TKI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Pfizer.
Disclosure
J.E. Shin: Financial Interests, Institutional, Funding: Pfizer.
Resources from the same session
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract